Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2023-12-01 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：独立董事关于第三届董事会第十七次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the proposal to reappoint the audit firm for the 2023 fiscal year. It references compliance with company law, stock exchange listing rules, and company articles of association. The content focuses on the approval and recommendation of the audit firm for the upcoming year, which is a governance-related matter concerning board decisions and audit arrangements. The document is short (773 characters) and does not contain financial statements or detailed audit results, so it is not an Audit Report (AR) or Annual Report (10-K). It is also not a report publication announcement or certification. The nature of the document aligns best with Board/Management Information (MANG), as it relates to board meeting matters and management decisions about audit firm appointment.
2023-12-01 Chinese
赛伦生物：《募集资金管理制度》（2023年12月）
Governance Information Classification · 95% confidence The document is a detailed internal policy or procedural document regarding the management and use of funds raised by Shanghai Sairen Biotechnology Co., Ltd. It extensively discusses the rules, responsibilities, and oversight related to the use of raised capital, including storage, usage, changes in use, supervision, and reporting requirements. It references regulatory frameworks and internal governance but does not present financial statements, earnings data, or audit results. It is not an announcement or a brief summary but a comprehensive governance document related to capital management. This fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including policies on capital management and use.
2023-12-01 Chinese
赛伦生物：《关联交易管理制度》（2023年12月）
Governance Information Classification · 95% confidence The document is a detailed policy and procedural document regarding related party transactions (关联交易) for Shanghai Sairen Biotechnology Co., Ltd. It outlines definitions, principles, approval processes, pricing methods, and governance related to transactions between the company and its related parties. The content is regulatory and governance-focused, detailing internal rules and compliance with laws and stock exchange listing rules. There are no financial statements, earnings data, or audit opinions present. The document is not an announcement or a brief notice but a comprehensive governance policy document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-12-01 Chinese
独立董事候选人声明与承诺（叶榅平）
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate of Shanghai Sailun Biotechnology Co., Ltd. It details the candidate's qualifications, compliance with relevant laws and regulations, and commitment to fulfill the duties of an independent director. There is no financial data, no report or announcement of financial results, no voting results, no management changes, and no regulatory filings of other types. The document is a formal statement related to board/management information, specifically about the nomination and qualifications of a board member candidate. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report but a declaration by the candidate.
2023-12-01 Chinese
赛伦生物：关于召开2023年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2023 first extraordinary general meeting of shareholders for Shanghai Serum BioTech Co., Ltd. It includes information about the meeting date, voting methods, agenda items, shareholder registration, proxy forms, and cumulative voting procedures for electing directors and independent directors. It does not contain financial statements or results but is focused on the announcement and procedural details of the shareholder meeting. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. The document is over 5,000 characters and is not merely an announcement of a report publication, so it is not an RPA. It is not an AGM Information presentation (AGM-R) because it is a notice of the meeting, not materials shared during the AGM. Therefore, the best classification is PSI.
2023-12-01 Chinese
赛伦生物：《对外担保管理制度》（2023年12月）
Governance Information Classification · 95% confidence The document is a detailed internal policy document regarding the company's external guarantee (担保) practices, including definitions, conditions, approval processes, responsibilities, and disclosure obligations. It references company laws, regulatory guidelines, and internal governance rules. There is no indication that this is a financial report, audit report, earnings release, or any form of shareholder meeting material. It is not a brief announcement or a certification. The document is a governance-related policy outlining internal rules and procedures for managing external guarantees, which aligns with Governance Information (CGR).
2023-12-01 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.